tbuckley/cabot-search huggingface dataset:
β3 adrenergic agonist treatment in chronic pulmonary hypertension associated with heart failure (<scp>SPHERE‐HF</scp>): a double blind, placebo‐controlled, randomized clinical trial
Authors: Ana García‐Álvarez, Isabel Blanco, Inés García‐Lunar, Paloma Jordà, Juan J. Rodriguez‐Arias, Leticia Fernández‐Friera, Isabel Zegri, Jorge Nuche, Manuel Gomez‐Bueno, Susanna Prat, Sandra Pujadas, Eduard Sole‐Gonzalez, Maria D. Garcia‐Cossio, Mercedes Rivas, Estefanía Torrecilla, Daniel Pereda, Javier Sanchez, Pablo García‐Pavía, Javier Segovia‐Cubero, Juan F Delgado, Sonia Mirabet, Valentín Fuster, Joan A. Barberá, Borja Ibañez
Journal: European Journal of Heart Failure (2022)

Pulmonary hypertension (PH) associated with left heart disease is an increasingly prevalent problem, orphan of targeted therapies, and related to a poor prognosis, particularly when pre- and post-capillary PH combine. The current study aimed to determine whether treatment with the selective β3 adrenoreceptor agonist mirabegron improves outcomes in patients with combined pre- and post-capillary PH (CpcPH).The β3 Adrenergic Agonist Treatment in Chronic Pulmonary Hypertension Secondary to Heart Failure (SPHERE-HF) trial is a multicentre, randomized, parallel, placebo-controlled clinical trial that enrolled stable patients with CpcPH associated with symptomatic heart failure. A total of 80 patients were assigned to receive mirabegron (50 mg daily, titrated till 200 mg daily, n = 39) or placebo (n = 41) for 16 weeks. Of them, 66 patients successfully completed the study protocol and were valid for the main analysis. The primary endpoint was the change in pulmonary vascular resistance (PVR) on right heart catheterization. Secondary outcomes included the change in right ventricular (RV) ejection fraction by cardiac magnetic resonance or computed tomography, other haemodynamic variables, functional class, and quality of life. The trial was negative for the primary outcome (placebo-corrected mean difference of 0.62 Wood units, 95% confidence interval [CI] -0.38, 1.61, p = 0.218). Patients receiving mirabegron presented a significant improvement in RV ejection fraction as compared to placebo (placebo-corrected mean difference of 3.0%, 95% CI 0.4, 5.7%, p = 0.026), without significant differences in other pre-specified secondary outcomes.SPHERE-HF is the first clinical trial to assess the potential benefit of β3 adrenergic agonists in PH. The trial was negative since mirabegron did not reduce PVR, the primary endpoint, in patients with CpcPH. On pre-specified secondary outcomes, a significant improvement in RV ejection fraction assessed by advanced cardiac imaging was found, without differences in functional class or quality of life.
An effective and chemotherapy-free strategy of all-trans retinoic acid and arsenic trioxide for acute promyelocytic leukemia in all risk groups (APL15 trial)
Authors: Huai-Yu Wang, Sha Gong, Guo-Hui Li, Ya-Zhou Yao, Yin-Suo Zheng, Xiao-Hong Lu, Su-Hua Wei, Wei-Wei Qin, Hai-Bo Liu, Meng-Chang Wang, Jie-Ying Xi, Li-Mei Chen, Mei Zhang, Xin-Xin Zhang, Hui-Yun Zhang, Cheng-Sheng Zhang, David N. Wald, Hong-Hu Zhu, Li Liu, Peng-Cheng He
Journal: Blood Cancer Journal (2022)

Abstract The combination of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) has been demonstrated to have comparable effectiveness or better to ATRA and chemotherapy (CHT) in non-high-risk acute promyelocytic leukemia (APL). However, the efficacy of ATRA-ATO compared to ATRA-ATO plus CHT in high-risk APL remains unknown. Here we performed a randomized multi-center non-inferiority phase III study to compare the efficacy of ATRA-ATO and ATRA-ATO plus CHT in newly diagnosed all-risk APL to address this question. Patients were assigned to receive ATRA-ATO for induction, consolidation, and maintenance or ATRA-ATO plus CHT for induction followed by three cycles of consolidation therapy, and maintenance therapy with ATRA-ATO. In the non-CHT group, hydroxyurea was used to control leukocytosis. A total of 128 patients were treated. The complete remission rate was 97% in both groups. The 2-year disease-free, event-free survival rates in the non-CHT group and CHT group in all-risk patients were 98% vs 97%, and 95% vs 92%, respectively ( P = 0.62 and P = 0.39, respectively). And they were 94% vs 87%, and 85% vs 78% in the high-risk patients ( P = 0.52 and P = 0.44, respectively). This study demonstrated that ATRA-ATO had the same efficacy as the ATRA-ATO plus CHT in the treatment of patients with all-risk APL.
Validation of the revised diagnostic criteria for primary plasma cell leukemia by the Korean Multiple Myeloma Working Party
Authors: Sung-Hoon Jung, Kihyun Kim, Sang Eun Yoon, Joon Ho Moon, Dajung Kim, Hyo Jung Kim, Min Kyoung Kim, Kyoung Ha Kim, Hyun Jung Lee, Ji Hyun Lee, Sung-Hyun Kim, Kawi Han Yoo, Jae Hoon Lee, Je-Jung Lee
Journal: Blood Cancer Journal (2022)

The International Myeloma Working Group has recently revised the diagnostic criteria for primary plasma cell leukemia (PCL) to circulating plasma cells (CPCs) ≥ 5% in a peripheral blood smear. The present study validated new criteria in patients with multiple myeloma or PCL diagnosed using the previous diagnostic criteria, who were administered immunomodulatory drugs or proteasome inhibitors as induction therapy. We analyzed the medical records of 1357 patients from eight hospitals in South Korea. The median age of the all patients was 64 years, and 187 (13.8%) had CPCs at diagnosis. Only 79 (5.8%) of the patients had ≥ 5% CPCs. The median overall survival (OS) of patients with CPCs ≥ 5% and ≥ 20% was similar, but had significantly inferior median progression-free survival (PFS) and median OS than those with CPCs < 5% (13.1 vs. 21.5 months, P < 0.001, and 21.5 vs. 60.9 months, P < 0.001, respectively). Primary PCL diagnosed using the revised criteria presented with higher total calcium levels and serum creatinine levels, lower platelet counts and frequent organomegaly and plasmacytoma at diagnosis. Univariate and multivariate analyses demonstrated that the presence of plasmacytoma and elevated serum β2-microglobulin were significantly associated with OS in primary PCL. In conclusion, the revised criterion of CPCs ≥ 5% in a peripheral blood smear is appropriate for PCL diagnosis.
Boosting ROS‐Mediated Lysosomal Membrane Permeabilization for Cancer Ferroptosis Therapy
Authors: Ying Chen, Zengqiu Yang, Sibu Wang, Qin Ma, Lingyan Li, Xingjie Wu, Qianqian Guo, Ling Tao, Xiangchun Shen
Journal: Advanced Healthcare Materials (2022)

Abstract Due to the deficient catalase, abundant reduced iron and low acidic environment in lysosomes, inducing lysosomal membrane permeabilization (LMP) through Fenton reaction‐based reactive oxygen species (ROS) generation recently attracts increasing attention in cancer therapy. However, the lysosomal membranes are protected by highly glycosylated membrane proteins and several endolysosomal damage‐response mechanisms can rapidly repair the injured lysosomes. To produce sufficient ROS and cause complete lysosomal membranes rupture, a lysosome‐targeted ROS inducer, N ‐(3‐Aminopropyl) morpholine grafted cross‐linked lipoic acid vesicles with vitamin C‐loading (VC@ N3AM cLAVs), is developed. VC@ N3AM cLAVs efficiently accumulate in lysosomes and convert into two redox couples LA/DHLA (dihydrolipoic acid, reduced form of LA) and VC/DHA (dehydroascorbic acid, oxidized form of VC) by the lysosomal glutathione, which can not only produce a large amount of H 2 O 2 by pro‐oxidant action but also accelerate iron transformation through the cyclic redox reactions between each other and cause the efficient conversion of the generated H 2 O 2 into highly toxic •OH. Both in vitro and in vivo experiments demonstrate that VC@ N3AM cLAVs can effectively enhance ROS production and boost LMP, finally initiation irreversible death of tumor cells via ferroptosis pathway, thus representing a potential anticancer drug for cancer therapy.
<i>GTF3A</i> mutations predispose to herpes simplex encephalitis by disrupting biogenesis of the host-derived RIG-I ligand <i>RNA5SP141</i>
Authors: Leslie Naesens, Santoshi Muppala, Dhiraj Acharya, Josephine Nemegeer, Delfien Bogaert, Jung-Hyun Lee, Katrien Staes, Veronique Debacker, Pieter De Bleser, Marieke De Bruyne, Elfride De Baere, Michiel van Gent, GuanQun Liu, Bart N. Lambrecht, Jens Staal, Tessa Kerre, Rudi Beyaert, Jonathan Maelfait, Simon J. Tavernier, Michaela U. Gack, Filomeen Haerynck
Journal: Science Immunology (2022)

Herpes simplex virus 1 (HSV-1) infects several billion people worldwide and can cause life-threatening herpes simplex encephalitis (HSE) in some patients. Monogenic defects in components of the type I interferon system have been identified in patients with HSE, emphasizing the role of inborn errors of immunity underlying HSE pathogenesis. Here, we identify compound heterozygous loss-of-function mutations in the gene GTF3A encoding for transcription factor IIIA (TFIIIA), a component of the RNA polymerase III complex, in a patient with common variable immunodeficiency and HSE. Patient fibroblasts and GTF3A gene-edited cells displayed impaired HSV-1-induced innate immune responses and enhanced HSV-1 replication. Chromatin immunoprecipitation sequencing analysis identified the 5S ribosomal RNA pseudogene 141 (RNA5SP141), an endogenous ligand of the RNA sensor RIG-I, as a transcriptional target of TFIIIA. GTF3A mutant cells exhibited diminished RNA5SP141 expression and abrogated RIG-I activation upon HSV-1 infection. Our work unveils a crucial role for TFIIIA in transcriptional regulation of a cellular RIG-I agonist and shows that GTF3A genetic defects lead to impaired cell-intrinsic anti-HSV-1 responses and can predispose to HSE.
<i>Lactobacillus johnsonii</i> alleviates colitis by TLR1/2-STAT3 mediated CD206 <sup>+</sup> macrophages <sup>IL-10</sup> activation
Authors: Ding-Jia-Cheng Jia, Qi-Wen Wang, Ying-Ying Hu, Jia-Min He, Qi-Wei Ge, Ya-Dong Qi, Lu-Yi Chen, Ying Zhang, Li-Na Fan, Yi-Feng Lin, Yong Sun, Yao Jiang, Lan Wang, Yan-Fei Fang, Hui-Qin He, Xiong-E Pi, Wei Liu, Shu-Jie Chen, Liang-Jing Wang
Journal: Gut Microbes (2022)

Imbalance of gut microbiota homeostasis is related to the occurrence of ulcerative colitis (UC), and probiotics are thought to modulate immune microenvironment and repair barrier function. Here, in order to reveal the interaction between UC and gut microbiota, we screened a new probiotic strain by 16S rRNA sequencing from Dextran Sulfate Sodium (DSS)-induced colitis mice, and explored the mechanism and clinical relevance. Lactobacillus johnsonii (L. johnsonii), as a potential anti-inflammatory bacterium was decreased colonization in colitis mice. Gavage L. johnsonii could alleviate colitis by specifically increasing the proportion of intestinal macrophages and the secretion of Il-10 with macrophages depleted model and in Il10−/− mice. We identified this subset of immune cells activated by L. johnsonii as CD206+ macrophagesIL−10. Mechanistically, L. johnsonii supplementation enhanced the mobilization of CD206+ macrophagesIL−10 through the activation of STAT3 in vivo and in vitro. In addition, we revealed that TLR1/2 was essential for the activation of STAT3 and the recognition of L. johnsonii by macrophages. Clinically, there was positive correlation between the abundance of L. johnsonii and the expression level of MRC1, IL10 and TLR1/2 in UC tissues. L. johnsonii could activate native macrophages into CD206+ macrophages and release IL-10 through TLR1/2-STAT3 pathway to relieve experimental colitis. L. johnsonii may serve as an immunomodulator and anti-inflammatory therapeutic target for UC.
Native T1 Mapping for the Diagnosis of Myocardial Fibrosis in Patients With Chronic Myocardial Infarction
Authors: Yodying Kaolawanich, Clerio F. Azevedo, Han W. Kim, Elizabeth R. Jenista, David C. Wendell, Enn-ling Chen, Michele A. Parker, Robert M. Judd, Raymond J. Kim
Journal: JACC. Cardiovascular imaging (2022)
An interpretable RL framework for pre-deployment modeling in ICU hypotension management
Authors: Kristine Zhang, Henry Wang, Jianzhun Du, Brian Chu, Aldo Robles Arévalo, Ryan Kindle, Leo Anthony Celi, Finale Doshi-Velez
Journal: npj Digital Medicine (2022)

Abstract Computational methods from reinforcement learning have shown promise in inferring treatment strategies for hypotension management and other clinical decision-making challenges. Unfortunately, the resulting models are often difficult for clinicians to interpret, making clinical inspection and validation of these computationally derived strategies challenging in advance of deployment. In this work, we develop a general framework for identifying succinct sets of clinical contexts in which clinicians make very different treatment choices, tracing the effects of those choices, and inferring a set of recommendations for those specific contexts. By focusing on these few key decision points, our framework produces succinct, interpretable treatment strategies that can each be easily visualized and verified by clinical experts. This interrogation process allows clinicians to leverage the model’s use of historical data in tandem with their own expertise to determine which recommendations are worth investigating further e.g. at the bedside. We demonstrate the value of this approach via application to hypotension management in the ICU, an area with critical implications for patient outcomes that lacks data-driven individualized treatment strategies; that said, our framework has broad implications on how to use computational methods to assist with decision-making challenges on a wide range of clinical domains.
A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes
Authors: Veeral Ajmera, Sandra Cepin, Kaleb Tesfai, Heather Hofflich, Karen Cadman, Scarlett Lopez, Egbert Madamba, Ricki Bettencourt, Lisa Richards, Cynthia Behling, Claude B. Sirlin, Rohit Loomba
Journal: Journal of Hepatology (2022)
Where is the error? Hierarchical predictive coding through dendritic error computation
Authors: Fabian A. Mikulasch, Lucas Rudelt, Michael Wibral, Viola Priesemann
Journal: Trends in Neurosciences (2022)

Top-down feedback in cortex is critical for guiding sensory processing, which has prominently been formalized in the theory of hierarchical predictive coding (hPC). However, experimental evidence for error units, which are central to the theory, is inconclusive and it remains unclear how hPC can be implemented with spiking neurons. To address this, we connect hPC to existing work on efficient coding in balanced networks with lateral inhibition and predictive computation at apical dendrites. Together, this work points to an efficient implementation of hPC with spiking neurons, where prediction errors are computed not in separate units, but locally in dendritic compartments. We then discuss the correspondence of this model to experimentally observed connectivity patterns, plasticity, and dynamics in cortex.
Anatomical barriers against SARS-CoV-2 neuroinvasion at vulnerable interfaces visualized in deceased COVID-19 patients
Authors: Mona Khan, Marnick Clijsters, Sumin Choi, Wout Backaert, Michiel Claerhout, Floor Couvreur, Laure Van Breda, Florence Bourgeois, Kato Speleman, Sam Klein, Johan Van Laethem, Gill Verstappen, Ayse Sumeyra Dereli, Seung-Jun Yoo, Hai Zhou, Thuc Nguyen Dan Do, Dirk Jochmans, Lies Laenen, Yves Debaveye, Paul De Munter, Jan Gunst, Mark Jorissen, Katrien Lagrou, Philippe Meersseman, Johan Neyts, Dietmar Rudolf Thal, Vedat Topsakal, Christophe Vandenbriele, Joost Wauters, Peter Mombaerts, Laura Van Gerven
Journal: Neuron (2022)

Can SARS-CoV-2 hitchhike on the olfactory projection and take a direct and short route from the nose into the brain? We reasoned that the neurotropic or neuroinvasive capacity of the virus, if it exists, should be most easily detectable in individuals who died in an acute phase of the infection. Here, we applied a postmortem bedside surgical procedure for the rapid procurement of tissue, blood, and cerebrospinal fluid samples from deceased COVID-19 patients infected with the Delta, Omicron BA.1, or Omicron BA.2 variants. Confocal imaging of sections stained with fluorescence RNAscope and immunohistochemistry afforded the light-microscopic visualization of extracellular SARS-CoV-2 virions in tissues. We failed to find evidence for viral invasion of the parenchyma of the olfactory bulb and the frontal lobe of the brain. Instead, we identified anatomical barriers at vulnerable interfaces, exemplified by perineurial olfactory nerve fibroblasts enwrapping olfactory axon fascicles in the lamina propria of the olfactory mucosa.
One model is all you need: Multi-task learning enables simultaneous histology image segmentation and classification
Authors: Simon Graham, Quoc Dang Vu, Mostafa Jahanifar, Shan E Ahmed Raza, Fayyaz Minhas, David Snead, Nasir Rajpoot
Journal: Medical Image Analysis (2022)

The recent surge in performance for image analysis of digitised pathology slides can largely be attributed to the advances in deep learning. Deep models can be used to initially localise various structures in the tissue and hence facilitate the extraction of interpretable features for biomarker discovery. However, these models are typically trained for a single task and therefore scale poorly as we wish to adapt the model for an increasing number of different tasks. Also, supervised deep learning models are very data hungry and therefore rely on large amounts of training data to perform well. In this paper, we present a multi-task learning approach for segmentation and classification of nuclei, glands, lumina and different tissue regions that leverages data from multiple independent data sources. While ensuring that our tasks are aligned by the same tissue type and resolution, we enable meaningful simultaneous prediction with a single network. As a result of feature sharing, we also show that the learned representation can be used to improve the performance of additional tasks via transfer learning, including nuclear classification and signet ring cell detection. As part of this work, we train our developed Cerberus model on a huge amount of data, consisting of over 600 thousand objects for segmentation and 440 thousand patches for classification. We use our approach to process 599 colorectal whole-slide images from TCGA, where we localise 377 million, 900 thousand and 2.1 million nuclei, glands and lumina respectively. We make this resource available to remove a major barrier in the development of explainable models for computational pathology.
Corrigendum to “The RNA binding protein HuR influences skeletal muscle metabolic flexibility in rodents and humans” [Metab. 97 (2019) 40–49]
Authors: Randall L. Mynatt, Robert C. Noland, Carrie M. Elks, Bolormaa Vandanmagsar, David S. Bayless, Allison C. Stone, Sujoy Ghosh, Eric Ravussin, Jaycob D. Warfel
Journal: Metabolism (2022)
Disease-driven engineering of peptide-targeted DM1 loaded liposomal nanoparticles for enhanced efficacy in treating multiple myeloma by exploring DM1 prodrug chemistry
Authors: Sabrina Khan, Franklin Mejia, Jaeho Shin, Gyoyeon Hwang, David T. Omstead, Junmin Wu, Sara L. Cole, Laurie E. Littlepage, Basar Bilgicer
Journal: Biomaterials (2022)
Table of Contents
Authors: Larissa Govers, Olivier Devuyst, Tilman Drüeke, Ziad Massy, Anqun Chen, Kyung Lee, John Cijiang He, Haojia Wu, Benjamin Humphreys, Paul Perco, Gert Mayer, Sho Hasegawa, Donna Reidlinger, David Johnson, Jonathan Craig, Stephen Mcdonald, Alistair Mallard, Laura Robison, Germaine Wong, Carmel Hawley, Paul Martin, Ahmed Awan, Marina Berenguer, Annette Bruchfeld, Fabrizio Fabrizi, David Goldberg, Jidong Jia, Nassim Kamar, Rosmawati Mohamed, Guimarães Pessôa, Stanislas Pol, Meghan Sise, Ethan Balk, Craig Gordon, Gaelen Adam, Michael Cheung, Amy Earley, Michel Jadoul, María Castañeda-Bueno, David Ellison, Yuanzhi Ye, Li Li, Qingchun Liang, Siyi Wang, Qianqian Dong, Mingwei Fu, Zirong Lan, Yining Li, Xiaoyu Liu, Jing-Song Ou, Lihe Lu, Jianyun Yan, Etsuko Toda, Anri Sawada, Kazuhiro Takeuchi, Kyoko Wakamatsu, Arimi Ishikawa, Naomi Kuwahara, Yurika Sawa, Saeko Hatanaka, Kana Kokubo, Kosho Makino, Hideyo Takahashi, Yoko Endo, Shinobu Kunugi, Mika Terasaki, Yasuhiro Terasaki, Kouji Matsushima, Yuya Terashima, Akira Shimizu, Jia Fu, Zeguo Sun, Xuan Wang, Tuo Zhang, Weijie Yuan, Fadi Salem, Samuel Mon-, Wei Yu, Weijia Zhang, Floris Valentijn, Sebastiaan Knoppert, Laura Marquez-Exposito, Raúl Rodrigues-Diez, Georgios Pissas, Jiaqi Tang, Lucia Tejedor-Santamaria, Roel Broekhuizen, Rohan Samarakoon, Theodoros Eleftheriadis, Roel Goldschmeding, Tri Nguyen, Marta Ruiz-Ortega, Lucas Falke, Xiaoming Fan, Xiaolu Zhang, Lijun Liu, Shungang Zhang, Cole Pelger, Haroon Lughmani, Steven Haller, William Gunning, Christopher Cooper, Rujun Gong, Lance Dworkin, Rajesh Gupta, Brandon Renner, Jennifer Laskowski, Felix Poppelaars, Viviana Ferreira, Judith Blaine, Alexandra Antonioli, Jonathan Hannan, James Kovacs, Cees Van Kooten, Zhiying You, Matthew Pickering, V Holers, Joshua Thurman
Journal: Kidney International (2022)
Liquid crystal elastomer based dynamic device for urethral support: Potential treatment for stress urinary incontinence
Authors: Seelay Tasmim, Zuha Yousuf, Farial S. Rahman, Emily Seelig, Abigail J. Clevenger, Sabrina N. VandenHeuvel, Cedric P. Ambulo, Shreya Raghavan, Philippe E. Zimmern, Mario I. Romero-Ortega, Taylor H. Ware
Journal: Biomaterials (2022)
Advisory Board and Contents
Authors: Pawel Burkhardt, Stephanie King, Richard Connor, Stephen Montgomery, Kris Yue, Christoph Wu, Julijana Miehl, Kasey Girven, Leandra Mangieri, Michael Bruchas, Oliver Kann, Fadi Almouhanna, Bruno Chausse, Ellen Schill, Alexandria Floyd, Rodney Newberry, Kaitlyn Hajdarovic, Doudou Yu, Ashley Webb, Moran Furman, Danielle Loughlin, Fred Kop, Patrick Scheffmann, Silvia Arber, Emery Brown, Rui Costa, Ann Craig, John Cryan, Catherine Dulac, Yukiko Goda, Kenneth Harris, Nancy Ip, Meyer Jackson, Maria Karayiorgou, Nancy Kopell, Robert Malenka, Mark Mattson, Freda Miller, Richard Morris, Maiken Nedergaard, Eric Nestler, Kia Nobre, Marco Prinz, Anna Wang, Roe Carmen, Sandi Klaas, Enno Stephan, Greg Stuart, Christopher Walsh, Xiaoqin Wang, Xu Zhang
Journal: Trends in Neurosciences (2022)
Human monkeypox virus infection in women and non-binary individuals during the 2022 outbreaks: a global case series
Authors: John P Thornhill, Romain Palich, Jade Ghosn, Sharon Walmsley, Davide Moschese, Claudia P Cortes, Rafael Mello Galliez, Amy B Garlin, Silvia Nozza, Oriol Mitja, Asa E Radix, Jose Luis Blanco, Brenda Crabtree-Ramirez, Melanie Thompson, Lothar Wiese, Hubert Schulbin, Ariela Levcovich, Marco Falcone, Anna Lucchini, Elena Sendagorta, Carl-Johan Treutiger, Ruth Byrne, Katherine Coyne, Eric A Meyerowitz, Anna M Grahn, Ann-Brit Eg Hansen, Valerie Pourcher, Michelle DellaPiazza, Rachel Lee, Marcel Stoeckle, Aniruddha Hazra, Vanessa Apea, Emma Rubenstein, Joyce Jones, Aimee Wilkin, Anuradha Ganesan, Andrés F Henao-Martínez, Eric J Chow, Boghuma K Titanji, Jason E Zucker, Dimie Ogoina, Chloe M Orkin
Journal: The Lancet (2022)
Error in Table
Journal: JAMA Network Open (2022)

David R. Strong, PhD; John P. Pierce, PhD; Kim Pulvers, PhD; Matthew D. Stone, MS; Adriana Villaseñor, PhD; Minya Pu, MA; Claudiu V. Dimofte, PhD; Eric C. Leas, PhD; Jesica Oratowski, MPH; Elizabeth Brighton, BS; Samantha Hurst, PhD; Sheila Kealey, MPH; Ruifeng Chen, MS; Karen Messer, PhD